Sign up to save your podcasts
Or
Share Dr Robert Hess: We are now several months into the vaccination campaign, and it is clear to us from our own SARS-CoV-2..
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr Robert Hess: We are now several months into the vaccination campaign, and it is clear to us from our own SARS-CoV-2..
... SARS-CoV-2 antibody and immunization testing that the track record of the vaccines is very disappointing, with more side-effects than originally expected. We therefore intend to have a personalized vaccine combination in place for 2022.
In contrast to the phase 3 data published by the various vaccine manufacturers, some of which claim headline rates of more than 90% efficacy, the test results that have come back from our clients indicate none of the vaccines has achieved this sort of success. Based on the clinical data and biochemical evaluations that we carry out at regular three-monthly intervals, we conclude that the levels actually attained are considerably lower. Antibody production and quality in particular reveal a significantly lower immunization status. This applies to all vaccines.
View all episodes
By Dr Robert Hess... SARS-CoV-2 antibody and immunization testing that the track record of the vaccines is very disappointing, with more side-effects than originally expected. We therefore intend to have a personalized vaccine combination in place for 2022.
In contrast to the phase 3 data published by the various vaccine manufacturers, some of which claim headline rates of more than 90% efficacy, the test results that have come back from our clients indicate none of the vaccines has achieved this sort of success. Based on the clinical data and biochemical evaluations that we carry out at regular three-monthly intervals, we conclude that the levels actually attained are considerably lower. Antibody production and quality in particular reveal a significantly lower immunization status. This applies to all vaccines.